[1]
Deryck O., Ketelaer P., Dubois B.: Clinical characteristics and long term prognosis in early onset multiple sclerosis. J Neurol 2006; 253: 720-723.
[2]
Hauser S. L., Oksenberg J. R.: The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron 2006; 52: 61-76.
[3]
Koch-Henriksen N., Sørensen P. S.: The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol 2010; 9: 520-532.
[4]
Ciccarelli O., Barkhof F., Bodini B., et al.: Pathogenesis of multiple sclerosis: insights from molecular and metabolic imaging. Lancet Neurol 2014; 13: 807-822.
[5]
Raine C. S.: The Norton Lecture: A review of the oligodendrocyte in the multiple sclerosis lesion. J Neuroimmunol 1997; 77: 135-152.
[6]
Lucchinetti C., Brück W., Parisi J., et al.: Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47: 707-717.
[7]
Bramow S., Frischer J. M., Lassmann H., et al.: Demyelination versus remyelination in progressive multiple sclerosis. Brain 2010; 133: 2983-2998.
[8]
Stasiolek M., Bayas A., Kruse N., et al.: Impaired maturation and altered regulatory function of plasmacytoid dendritic cells in multiple sclerosis. Brain 2006; 129: 1293-1305.
[9]
Stasiolek M., Linker R. A., Hayardeny L., et al.: Immune parameters of patients treated with laquinimod, a novel oral therapy for the treatment of multiple sclerosis: results from a double-blind placebo-controlled study. Immun Inflamm Dis 2015; 3: 45-55.
[10]
Lino A. C., Dörner T., Bar-Or A., et al.: Cytokine-producing B cells: a translational view on their roles in human and mouse autoimmune diseases. Immunol Rev 2016; 269: 130-144.
[11]
Matysiak M., Stasiołek M., Orłowski W., et al.: Stem cells ameliorate EAE via an indoleamine 2,3-dioxygenase (IDO) mechanism. J Neuroimmunol 2008; 193: 12-23.
[12]
Stasiolek M.: The role of selected immunoregulatory cell populations in autoimmune demyelination. Neuro Endocrinol Lett 2011; 32: 25-33.
[13]
Stangel M., Penner I. K., Kallmann B. A., et al.: Towards the implementation of ‚no evidence of disease activity’ in multiple sclerosis treatment: the multiple sclerosis decision model. Ther Adv Neurol Disord 2015; 8: 3-13.
[14]
Chitnis T., Glanz B., Jaffin S., et al.: Demographics of pediatric-onset multiple sclerosis in an MS center population from the Northeastern United States. Mult Scler 2009; 15: 627-631.
[15]
Gorman M. P., Healy B. C., Polgar-Turcsanyi M., Chitnis T.: Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol. 2009 Jan; 66(1): 54-59.
[16]
Boiko A., Vorobeychik G., Paty D., et al.: Early onset multiple sclerosis: a longitudinal study. Neurology 2002; 59: 1006-1010.
[17]
Banwell B., Bar-Or A., Cheung R., et al.: Abnormal T-cell reactivities in childhood inflammatory demyelinating disease and type 1 diabetes. Ann Neurol 2008; 63: 98-111.
[18]
Benson L. A., Healy B. C., Gorman M. P., et al.: Elevated relapse rates in pediatric compared to adult MS persist for at least 6 years. Mult Scler Relat Disord 2014; 3: 186-193.
[19]
Pfeifenbring S., Bunyan R. F., Metz I., et al.: Extensive acute axonal damage in pediatric multiple sclerosis lesions. Ann Neurol 2015; 77: 655-667.
[20]
Harding K. E., Liang K., Cossburn M. D., et al.: Long-term outcome of paediatric-onset multiple sclerosis: a population-based study. J Neurol Neurosurg Psychiatry 2013; 84: 141-147.
[21]
Suppiej A., Cainelli E.: Cognitive dysfunction in pediatric multiple sclerosis. Neuropsychiatr Dis Treat 2014; 10: 1385-1392.
[22]
La Mantia L., Vacchi L., Di Pietrantonj C., et al.: Interferon beta for secondary progressive multiple sclerosis. Cochrane Database Syst Rev 2012; 1: CD005181. doi: 10.1002/14651858.CD005181.pub3.
[23]
Kuhle J., Hardmeier M., Disanto G., et al.: A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis. Mult Scler 2015; pii: 1352458515594440.
[24]
Kieseier B. C.: The mechanism of action of interferon-β in relapsing multiple sclerosis. CNS Drugs 2011; 25: 491-502.
[25]
Johnston J., So T.Y.: First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview. Drugs 2012; 72: 1195-1211.
[26]
Pepinsky R. B., LePage D. J., Gill A., et al.: Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-beta-1a with preserved in vitro bioactivity. J Pharmacol Exp Ther 2001; 297: 1059-1066.
[27]
Arnold D. L., Calabresi P. A., Kieseier B. C., et al.: Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis. BMC Neurol 2014; 14: 240.
[28]
Baker D. P., Pepinsky R. B., Brickelmaier M., et al.: PEGylated interferon beta-1a: meeting an unmet medical need in the treatment of relapsing multiple sclerosis. J Interferon Cytokine Res 2010; 30: 777-785.
[29]
Ziemssen T., Schrempf W.: Glatiramer acetate: mechanisms of action in multiple sclerosis. Int Rev Neurobiol 2007; 79: 537-570.
[30]
La Mantia L., Di Pietrantonj C., Rovaris M., et al.: Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev 2014; 7: CD009333. doi: 10.1002/14651858.CD009333.pub2.
[31]
Farrell R., Kapoor R., Leary S., et al.: Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of Interferon-beta. Mult Scler 2008; 14: 212-218.
[32]
Khan O., Rieckmann P., Boyko A., et al.: Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann Neurol 2013; 73: 705-713.
[33]
Caporro M., Disanto G., Gobbi C., et al.: Two decades of subcutaneous glatiramer acetate injection: current role of the standard dose, and new high-dose low-frequency glatiramer acetate in relapsing-remitting multiple sclerosis treatment. Patient Prefer Adherence 2014; 8: 1123-1134.
[34]
Archelos J. J., Previtali S. C., Hartung H. P.: The role of integrins in immune-mediated diseases of the nervous system. Trends Neurosci 1999; 22: 30-38.
[35]
Polman C. H., O’Connor P. W., Havrdova E., et al.: A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910.
[36]
Rudick R. A., Stuart W. H., Calabresi P. A., et al.: Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354: 911-923.
[37]
Oturai A. B., Koch-Henriksen N., Petersen T., et al.: Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study. Eur J Neurol 2009; 16: 420-423.
[38]
Putzki N., Yaldizli O., Mäurer M., et al.: Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries. Eur J Neurol 2010; 17: 31-37.
[39]
McGuigan C., Craner M., Guadagno J., et al.: Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group. J Neurol Neurosurg Psychiatry 2015; pii: jnnp-2015-311100. doi: 10.1136/jnnp-2015-311100.
[40]
Kornek B., Aboul-Enein F., Rostasy K., et al.: Natalizumab therapy for highly active pediatric multiple sclerosis. JAMA Neurol 2013; 70: 469-475.
[41]
Talab R., Talabova M., Klzo L.: Natalizumab in the treatment of pediatric multiple sclerosis. Neuro Endocrinol Lett 2012; 33: 579-589.
[42]
Hyams J. S., Wilson D. C., Thomas A., et al.: Natalizumab therapy for moderate to severe Crohn disease in adolescents. J Pediatr Gastroenterol Nutr 2007; 44: 185-191.
[43]
Ruck T., Bittner S., Wiendl H., et al.: Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond. Int J Mol Sci 2015; 16: 16414-16439.
[44]
Hauser S. L., Waubant E., Arnold D. L., et al.: B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358: 676-688.
[45]
He D., Guo R., Zhang F., et al.: Rituximab for relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev 2013; 12: CD009130. doi: 10.1002/14651858.CD009130.pub3.
[46]
Radick L., Mehr S. R.: The Latest Innovations in the Drug Pipeline for Multiple Sclerosis. Am Health Drug Benefits 2015; 8: 448-453.
[47]
Salzer J., Lycke J., Wickström R., et al.: Rituximab in paediatric onset multiple sclerosis: a case series. J Neurol 2015 Nov 24 (e-pub).
[48]
Chun J., Hartung H. P.: Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol 2010; 33: 91-101.
[49]
Brinkmann V., Billich A., Baumruker T., et al.: Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 2010; 9: 883-897.
[50]
Kappos L., Radue E. W., O’Connor P., et al.: A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362: 387-401.
[51]
Cohen J. A., Barkhof F., Comi G., et al.: Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362: 402-415.
[52]
Gajofatto A., Turatti M., Monaco S., et al.: Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis. Drug Healthc Patient Saf 2015; 7: 157-167.
[53]
Chan A., de Seze J., Comabella M.: Teriflunomide in Patients with Relapsing-Remitting Forms of Multiple Sclerosis. CNS Drugs 2016; 30: 41-51.
[54]
Merrill J. E., Hanak S., Pu S. F., et al.: Teriflunomide reduces behavioral, electrophysiological, and histopathological deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitis. J Neurol 2009; 256: 89-103.
[55]
Vermersch P., Czlonkowska A., Grimaldi L. M., et al.: Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Mult Scler 2014; 20: 705-716.
[56]
Nicholas J. A., Boster A. L., Imitola J., et al.: Design of oral agents for the management of multiple sclerosis: benefit and risk assessment for dimethyl fumarate. Drug Des Devel Ther 2014; 8: 897-908.
[57]
Bomprezzi R.: Dimethyl fumarate in the treatment of relapsing-remitting multiple sclerosis: an overview. Ther Adv Neurol Disord 2015; 8: 20-30.
[58]
Havrdova E., Hutchinson M., Kurukulasuriya N.C., et al.: Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM. Evaluation of: Gold R., Kappos L., Arnold D., et al.: Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012; 367: 1098-107; and Fox R. J., Miller D. H., Phillips J. T., et al.: Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012; 367: 1087-97. Expert Opin Pharmacother 2013; 14: 2145-2156.
Scholar Google
PubMed